Section Arrow
NVCR.NASDAQ
- NovoCure Limited
Quotes are at least 15-min delayed:2025/08/26 01:38 EDT
Regular Hours
Last
 11.7
-0.73 (-5.87%)
Day High 
12.42 
Prev. Close
12.43 
1-M High
16.7 
Volume 
1.46M 
Bid
11.68
Ask
12.18
Day Low
11.65 
Open
12.41 
1-M Low
10.87 
Market Cap 
1.39B 
Currency USD 
P/E -- 
%Yield -- 
10-SMA 11.75 
20-SMA 11.58 
50-SMA 14.77 
52-W High 34.13 
52-W Low 10.87 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-1.56/-1.75
Enterprise Value
1.51B
Balance Sheet
Book Value Per Share
3.13
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
605.22M
Operating Revenue Per Share
4.51
Industry Comparison
Code Name   Last Change Change (%) P/E P/E Range
PFSAProfusa Inc0.4899-0.0101-2.02%-- 
DXCMDexCom75.96-6.3-7.66%57.93PE
MDTMedtronic plc92.04-0.67-0.72%25.68PE
BFLYButterfly Network1.55+0.03+1.97%-- 
ABTAbbott Laboratories131.87-0.72-0.54%16.64PE
Quotes are at least 15-min delayed:2025/08/26 01:38 EDT
Industry overview quotes are at least 15 minutes delayed
Business Description
NovoCure Ltd is an oncology company with a propreitary platform technology in United States. Its business involves the development, manufacture and commercialization of Tumor Treating Fields (TTFields) devices, including Optune Gio and Optune Lua, for the treatment of solid tumor cancers. Its pipeline consists of Trident, Lunar-2, Panova-3, Metis and other products and technologies for the treatment of Glioblastoma, Non-smell cell lung cancer and Pancreatic cancer. Geographically, the company derives majority of its revenue from the United States and rest from Germany, Japan and other markets.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.